In order to overcome the limitation of the 19-gauge needle, a EUS-guided fine-needle biopsy (EUS-FNB) device (Echotip Procore; Wilson Cook Medical Inc., Winston-Salem, North Carolina, USA) was developed. In a randomized trial, diagnostic sufficiency, technical performance, and safety profiles of the 22-gauge biopsy needle were comparable to those of the conventional 22-gauge aspiration needle for sampling of pancreatic mass [12]. In another prospective comparison study, the correct diagnosis rate of EUS-FNB was higher than that of EUS-FNA in the pancreatic mass group (86.8 % vs. 75 %, P = 0.046) [13]. Larghi et al. reported the prospective result of EUS-FNB in 61 patients with pancreatic masses [14]. EUS-FNB was technically feasible in 98 % of patients with a solid pancreatic mass. A suitable sample for histological evaluation was obtained in 88.5 % of the cases after only one single needle pass. However, no article was published on the yield of EUS-FNB using the new needle for AIP diagnosis. Further studies are required to assess the diagnostic performance of EUS-FNB and comparison study between EUS-TCB and EUS-FNB for the better histologic diagnosis of AIP is necessary.